StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2017, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 07 Jun 2017 16:18:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form 8-K Innovation Pharmaceutica For: Jun 05 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Innovation+Pharmaceutica++For%3A+Jun+05/12990509.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Innovation+Pharmaceutica++For%3A+Jun+05/12990509.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Innovation+Pharmaceutica++For%3A+Jun+05/12990509.html Wed, 07 Jun 2017 16:18:00 -0400 CTIX Cellceutix Announces Company Name Change to Innovation Pharmaceuticals Inc. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html Wed, 07 Jun 2017 16:05:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Announces Company Name Change to Innovation Pharmaceuticals Inc. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html Wed, 07 Jun 2017 16:05:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Announces Company Name Change to Innovation Pharmaceuticals Inc. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html Wed, 07 Jun 2017 16:05:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Announces Company Name Change to Innovation Pharmaceuticals Inc. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Company+Name+Change+to+Innovation+Pharmaceuticals+Inc./12990317.html Wed, 07 Jun 2017 16:05:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Anti-Cancer Drug Candidate’s p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html Tue, 30 May 2017 07:30:00 -0400 A.07249079 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Anti-Cancer Drug Candidate’s p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html Tue, 30 May 2017 07:30:00 -0400 A.07249079 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Anti-Cancer Drug Candidate’s p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html Tue, 30 May 2017 07:30:00 -0400 A.07249079 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Anti-Cancer Drug Candidate’s p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html Tue, 30 May 2017 07:30:00 -0400 A.07249079 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Anti-Cancer Drug Candidate’s p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Anti-Cancer+Drug+Candidate%E2%80%99s+p53+Activity+in+Acute+Myeloid+Leukemia+to+be+Presented+by+Independent+Researchers+at+the+2017+European+Hematology+Association+Annual+Meeting/12955388.html Tue, 30 May 2017 07:30:00 -0400 A.07249079 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Completes Patient Enrollment of Final Cohort in Phase 2 Trial of Brilacidin for Inflammatory Bowel Disease; Topline Results Anticipated in July http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html Thu, 18 May 2017 09:30:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Completes Patient Enrollment of Final Cohort in Phase 2 Trial of Brilacidin for Inflammatory Bowel Disease; Topline Results Anticipated in July http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html Thu, 18 May 2017 09:30:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Completes Patient Enrollment of Final Cohort in Phase 2 Trial of Brilacidin for Inflammatory Bowel Disease; Topline Results Anticipated in July http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html Thu, 18 May 2017 09:30:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Completes Patient Enrollment of Final Cohort in Phase 2 Trial of Brilacidin for Inflammatory Bowel Disease; Topline Results Anticipated in July http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Completes+Patient+Enrollment+of+Final+Cohort+in+Phase+2+Trial+of+Brilacidin+for+Inflammatory+Bowel+Disease%3B+Topline+Results+Anticipated+in+July/12921288.html Thu, 18 May 2017 09:30:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Provides Corporate Update; Significant Milestones Ahead as Multiple Mid-Phase Clinical Trials Set to Conclude http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html Wed, 10 May 2017 09:45:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Provides Corporate Update; Significant Milestones Ahead as Multiple Mid-Phase Clinical Trials Set to Conclude http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html Wed, 10 May 2017 09:45:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Provides Corporate Update; Significant Milestones Ahead as Multiple Mid-Phase Clinical Trials Set to Conclude http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html Wed, 10 May 2017 09:45:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Cellceutix Provides Corporate Update; Significant Milestones Ahead as Multiple Mid-Phase Clinical Trials Set to Conclude http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Provides+Corporate+Update%3B+Significant+Milestones+Ahead+as+Multiple+Mid-Phase+Clinical+Trials+Set+to+Conclude/12884274.html Wed, 10 May 2017 09:45:00 -0400 A.12013808 A.21285025 A.33615634 CTIX Form 10-Q Cellceutix CORP For: Mar 31 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cellceutix+CORP+++++++++++For%3A+Mar+31/12879885.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cellceutix+CORP+++++++++++For%3A+Mar+31/12879885.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cellceutix+CORP+++++++++++For%3A+Mar+31/12879885.html Tue, 09 May 2017 16:08:00 -0400 CTIX Form SC 13G/A Cellceutix CORP Filed by: Aruda Wayne O http://www.streetinsider.com/SEC+Filings/Form++SC+13GA+++Cellceutix+CORP++++++++++++++++++++++++Filed+by%3A+Aruda+Wayne+O/12830883.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++SC+13GA+++Cellceutix+CORP++++++++++++++++++++++++Filed+by%3A+Aruda+Wayne+O/12830883.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++SC+13GA+++Cellceutix+CORP++++++++++++++++++++++++Filed+by%3A+Aruda+Wayne+O/12830883.html Fri, 28 Apr 2017 12:50:00 -0400 CTIX Cellceutix Announces Details for Upcoming Investor and Shareholder Presentations http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html Wed, 19 Apr 2017 16:15:00 -0400 A.12013808 A.20922990 A.33615634 CTIX Cellceutix Announces Details for Upcoming Investor and Shareholder Presentations http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html Wed, 19 Apr 2017 16:15:00 -0400 A.12013808 A.20922990 A.33615634 CTIX Cellceutix Announces Details for Upcoming Investor and Shareholder Presentations http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html Wed, 19 Apr 2017 16:15:00 -0400 A.12013808 A.20922990 A.33615634 CTIX Cellceutix Announces Details for Upcoming Investor and Shareholder Presentations http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+Announces+Details+for+Upcoming+Investor+and+Shareholder+Presentations/12792986.html Wed, 19 Apr 2017 16:15:00 -0400 A.12013808 A.20922990 A.33615634 CTIX Cellceutix CEO Discusses Brilacidin Following Interim Trial Results for Treating Oral Mucositis and Inflammatory Bowel Disease http://www.streetinsider.com/Press+Releases/Cellceutix+CEO+Discusses+Brilacidin+Following+Interim+Trial+Results+for+Treating+Oral+Mucositis+and+Inflammatory+Bowel+Disease/12762135.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Cellceutix+CEO+Discusses+Brilacidin+Following+Interim+Trial+Results+for+Treating+Oral+Mucositis+and+Inflammatory+Bowel+Disease/12762135.html for the full story. http://www.streetinsider.com/Press+Releases/Cellceutix+CEO+Discusses+Brilacidin+Following+Interim+Trial+Results+for+Treating+Oral+Mucositis+and+Inflammatory+Bowel+Disease/12762135.html Mon, 10 Apr 2017 07:30:00 -0400 A.12013808 A.20922990 A.33615634 CTIX